What is it? Why is it important?

Recruiting study participants necessitates that they be adequately informed and formally consent to study participation.

 

A participant informed consent process should be in place, which includes the following documents:

  • The Participant Information Sheet (PIS): provides candidates considering study participation with the necessary information needed to understand the study, and enable them to make a sound decision whether to participate in the study
  • The Informed Consent Form (ICF): is handed out together with the PIS. It is the official document where participants confirm their agreement to participate in a study in writing, by dating and signing the document

 

Within the context of Patient and Public Involvement (PPI), patients can be valuable contributors by reviewing PIC/ICF documents. This improves clarity, readability, and participant understanding of the study, leading to better participant experience when deciding on study participation.

What do I need to do?

As a SP-INV:

  • Select and download the official PIS/ICF templates applicable to your study from the swissethics webpage (e.g. children, individuals without capacity, emergency patients). The template provides a standardized document structure and comprehensive guidance on the required content
  • As applicable, request PPIE support to obtain feedback on PIS/ICF or other recruitment material. Ask PPIE collaborators to highlight unclear wording or complex sections, assess readability, length, and overall clarity

 

In addition:

  • Establish an informed consent process according to your target population. Describe the informed consent process in your study protocol
  • Define processes to ensure only Ethics Committee (EC) approved PIS/ICF remain in circulation during study conduct. For Medical Device studies with risk-category C the PIS must also be submitted to Swissmedic
  • In the event of a multicentre study, adapt documents according to site specific layouts, and add site-specific contact details (i.e. local ECs approve PIS/ICF-site documents under their jurisdiction)
  • Ensure PIS and ICF are reviewed and approved by the EC before implementation. As with the study protocol, EC approval is based on a particular PIS/ICF version (e.g. document identification).

More

Based on:

  • Target group, additional legal requirements may apply to the informed consent process (e.g. children studies, where the legal guardian also approves study participation)
  • Participant language background, literacy skills, or cognitive reasons, the EC might approve an exemption to the written PIS/ICF form
  • Changes or amendments, require that identifiers are adapted accordingly (e.g. version numbers, release dates), and that the documents are re-approved by EC.

Where can I get help?

Your local Research Support Centre↧ can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

SCTO Research Tools & Resources

External Links

Swissethics – see in particular

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: Definition informed consent
  • 2.8 Informed consent of trial participants
  • II GCP Principles Nr. 2 Informed consent is an integral part of the ethical conduct of a trial

ISO 14155:2026 Medical devices - see in particular section (access liable to cost)

  • 5.8 Informed consent

Declaration of Helsinki – see in particular principles

  • 25 – 32 Free and informed Consent

Swiss Law

HRA – see in particular articles

  • Art. 7 Consent
  • Art. 8 Right to receive information
  • Chapter 2, section 2 Information and Consent

ClinO – see in particular articles

  • Art. 7 Information given to participants
  • Art. 8 Exemption to the written form

ClinO-MD - see in particular

  • Art. 3b Applicable provisions (refer to ClinO)

HRO – see in particular articles

  • Art. 8 Information given to participants
  • Art. 9 Exemption to written form
Abbreviations
  • CTU – Clinical Trials Unit
  • DMS – Document Management System
  • EC – Ethics Committee
  • ICF – Informed Consent Form
  • ICH-GCP – International Council for Harmonisation — Good Clinical Practice
  • ISO – International Organization for Standardization
  • PIS – Participant Information Sheet
  • PPIE – Patient and Public Involvement and Engagement
  • SP-INV – Sponsor Investigator
Development ↦ Documents ↦ Required Documents ↦ Participant Information
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Documents ↦ Required Documents ↦ Participant Information